Home
>
US Stocks
>
Corcept Therapeutics Inc
Corcept Therapeutics Inc
CORT

Corcept Therapeutics Inc

$19.656.87%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
19.01
Today Low/High
18.89 / 19.89
52 Week Low/High
$12.2 / $31.18
P/E ratio
24.29
Market Cap
$2.37B

Company Details

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing's syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.
Organisation
Corcept Therapeutics Inc
Headquaters
Menlo Park, California, United States
Employees
236
Industry
Health Technology
CEO
Joseph Belanoff

Discover more

Frequently Asked Questions

What is Corcept Therapeutics Inc share price today

Can Indians buy Corcept Therapeutics Inc shares?

How can I buy Corcept Therapeutics Inc shares from India?

Can Fractional shares of Corcept Therapeutics Inc be purchased?

What are the documents required to start investing in Corcept Therapeutics Inc stocks?

We are a SEBI registered investement advisor